Acute Respiratory Distress Syndrome- Pipeline Insight, 2025

DelveInsight’s, “Acute Respiratory Distress Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Respiratory Distress Syndrome: Understanding

Acute Respiratory Distress Syndrome: Overview

ARDS is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible. It is a severe lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury which leads to fluid build-up inside the tiny air sacs of the lungs, and surfactant breakdown. The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.

Usually, the first symptom of ARDS is shortness of breath, cough, and fever. Other signs and symptoms of ARDS are low blood oxygen, rapid breathing, and clicking, bubbling, or rattling sounds in the lungs when breathing. ARDS is generally characterized by three stages such as exudative stage, fibroproliferative (or proliferative) stage, resolution, and recovery stage. The exudative stage is the accumulation of protein, excessive fluid and inflammatory cells in the alveoli occur in the exudative stage. This phase usually is seen within the first 2 to 4 days after the onset of lung injury. Fibroproliferative (or proliferative) stage is the proliferation of connective tissue and other structural elements in the lungs in response to the initial lung injury. The chances of a patient having pneumonia sepsis and rupture of the lungs are very high in this stage. Resolution and Recovery are in this stage, the lung reorganizes and recovers. During this stage, lung function may continue to improve in patients. The fourth phase of ARDS is also seen according to some experts in which when some patients due to acute illness have continued health problems while some may experience anxiety, depression, and flashback memories of their critical illness, which are very similar to post-traumatic stress disorder. This stage is still an area under research.

Early recognition of ARDS is important for the timely initiation of lung-protective ventilation strategies. Even after attempts to improve the definition of the disease, ARDS remains under-recognized by clinicians. Oftentimes, when a diagnosis is made, it has been after a significant delay. Chest X-rays for the diagnosis of ARDS have relatively low sensitivity and specificity of approximately 70% when compared to CT scans. CXR performs better when the infiltrates are diffuse or patchy as opposed to focal. The use of CT scans and other imaging techniques in the diagnosis and management of ARDS has become increasingly important. Lung ultrasound is another modality that can be used as a bedside tool to facilitate the diagnosis of ARDS. Treatment of ARDS is supportive, including mechanical ventilation, prevention of stress ulcers and venous thromboembolism, and nutritional support. Good supportive care, as for all ICU patients, should include nutritional support with an aim for early enteral feeding, good glycemic control, deep venous thrombosis, and stress ulceration prophylaxis. It is important to identify and treat any underlying infections with antibiotics targeted at culture sensitivities and if unavailable, toward common organisms specific to the infection site. Other treatment options, which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.

""Acute Respiratory Distress Syndrome- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Respiratory Distress Syndrome pipeline landscape is provided which includes the disease overview and Acute Respiratory Distress Syndrome treatment guidelines. The assessment part of the report embraces, in depth Acute Respiratory Distress Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Respiratory Distress Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Respiratory Distress Syndrome.

Acute Respiratory Distress Syndrome Emerging Drugs Chapters

This segment of the Acute Respiratory Distress Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Respiratory Distress Syndrome Emerging Drugs

• GEn 1124: GEn1E Lifesciences

GEn 1124 is an investigative small molecule drug being developed in collaboration with GEn1E Lifesciences and Biomedical Advanced Research and Development Authority (BARDA),part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to support the development of the company's novel therapy for acute respiratory distress syndrome (ARDS), The drug candidate is mitogen activated protein kinase 14 inhibitors .Currently, the drug is in Phase II stage of its development for the treatment of acute respiratory distress syndrome.

• ALT-100: Aqualung Therapeutics Corp.

ALT-100 is a “First in Man” immune-based monoclonal antibody (mAb) being developed by Aqualung Therapeutics Corp. ALT-100 antibody is a revolutionary, next generation antibody therapy. The humanized antibody has been developed and optimized by Fusion Antibodies’ revolutionary CDRx humanization and ADD develop ability platforms. This humanized monoclonal antibody will block systemic inflammation and will improve survival in the ARDS. ALT-100 inhibits eNAMPT binding to TLR4. Currently the drug is in Phase II stage of clinical trial for the treatment of acute distress respiratory syndrome.

• STSA 1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd

STSA 1002 is an investigative recombinant anti-human C5a IgG1 monoclonal antibody which acts by targeting complement C5a inhibitors C5a by specifically binding to anaphylatoxin C5a, C5a loses its ability to bind to receptors and blocks C5a-induced Biological functions, such as neutrophil chemotaxis, degranulation and oxygen respiratory burst, etc., while not affecting C5 cleavage and the formation of membrane attack complex (MAC), retaining the bacteriolytic and bactericidal functions of the complement system, thereby achieving the treatment of viruses, etc. Severe pneumonia, acute lung injury or acute respiratory distress syndrome caused by factors. It is administered through oral and subcutaneous route. Currently, the drug is in Phase I/II stage of its development for the treatment of acute respiratory distress syndrome.

• Descartes 30: Cartesian Therapeutics

Descartes-30 is an off-the-shelf (allogeneic) MSC product engineered with Cartesian's RNA ArmorySM cell therapy platform. Descartes-30 expresses a unique combination of DNases in patients and delivers a targeted treatment directly to the site of disease which eliminates neutrophil extracellular traps which are a key driver of inflammation and clotting in acute respiratory distress syndrome. The drug candidate relies on cell replacements mechanism of action. Currently the drug is in Phase I/II stage of clinical trial for the treatment of acute respiratory distress syndrome.

Further product details are provided in the report……..

Acute Respiratory Distress Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Acute Respiratory Distress Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Acute Respiratory Distress Syndrome
• There are approx. 50+ key companies which are developing the therapies for Acute Respiratory Distress Syndrome. The companies which have their Acute Respiratory Distress Syndrome drug candidates in the most advanced stage, i.e. Phase II include,GEn1E Lifesciences
• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Respiratory Distress Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Respiratory Distress Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Respiratory Distress Syndrome drugs.

Acute Respiratory Distress Syndrome Report Insights

• Acute Respiratory Distress Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Respiratory Distress Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Respiratory Distress Syndrome drugs?
• How many Acute Respiratory Distress Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Respiratory Distress Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Respiratory Distress Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Respiratory Distress Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Staidson (Beijing) Biopharmaceuticals Co., Ltd
• Cartesian Therapeutics
• GEn1E Lifesciences
• Aqualung Therapeutics Corp.
• Theratome Bio
• Meridigen Biotech Co., Ltd.
• Dompé Farmaceutici S.p.A
• Veru Healthcare
• Windtree Therapeutics
• MiNK Therapeutics
• Avalo Therapeutics, Inc
• Cynata Therapeutics Limited
• Thiogenesis Therapeutics, Inc.
• Arch Biopartners
• Ibudilast

Key Products

• STSA 1002
• Descartes 30
• GEn 1124
• ALT-100
• Thera 101
• UMC119-06
• Reparixin
• Sabizabulin
• Sinapultide
• AGENT 797
• CERC-002
• CYP 001
• TTI 0102
• Metablok
• Ibudilast

Please Note: It will take 5-6 business days to complete the report upon order confirmation. Show more